We wish to inform you that the Board of Directors of Asarfi Hospital Limited ('the Company'), at its meeting held today i.e. on 07th August, 2025, has inter alia considered and approved ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 2.7 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Asarfi Hospital Limited's Board, at its meeting on 7th August 2025, approved the unaudited standalone and consolidated financial results for the quarter ended 30th June 2025. Revenue from Operations stood at Rs. 3,566.41 lakhs (standalone), up about 55.6% from Rs. 2,292.30 lakhs in Q1 FY25. Profit After Tax more than doubled to Rs. 319.64 lakhs (standalone) from Rs. 152.79 lakhs last year, with EPS at Rs. 1.62 vs Rs. 0.78. Total Income was Rs. 3,708.04 lakhs. On the consolidated basis, PAT was Rs. 312.11 lakhs on revenue of Rs. 3,568.11 lakhs. The Board also noted HDFC Bank's sanction of a Rs. 8.25 crore loan – Rs. 5.25 crore term loan for building an educational facility and Rs. 3.00 crore working capital for the Asarfi Cancer Unit. The statutory auditor (R K Thakkar & Co) issued an unqualified limited review report.
Strong YoY growth in both revenue and profits signals healthy operational momentum and expansion, while the new HDFC Bank funding supports the company's educational and cancer care expansion plans. Short-term positive for shareholders, though the new borrowings will modestly increase debt servicing obligations.